A blood test for hidden colon cancer risk?
NCT ID NCT07776548
First seen Aug 20, 2026 · Last updated Aug 21, 2026 · Updated 1 time
Summary
This study is testing whether a blood test can detect DNA fragments shed by large, precancerous colorectal growths called laterally spreading tumors (LSTs). Researchers will collect blood samples from 110 adults before they undergo endoscopic removal of these lesions, then analyze the blood for tumor-specific DNA. They will also check whether this DNA test can predict if the growth will come back after removal. The goal is to see if a simple blood draw could help detect these high-risk polyps and monitor patients after treatment.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Blood collection for circulating tumour DNA (ctDNA) analysis
- What this could lead to
- If successful, this could lead to a simple blood test to detect precancerous colorectal growths and monitor for recurrence, potentially reducing the need for invasive follow-up procedures.
- What could go wrong
- This is an early-stage study with a small number of participants. The blood test may not be sensitive enough to detect ctDNA from these early lesions, and results may not generalize to broader populations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 110 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jan 2027
An estimate. Start dates often move.
- Expected to finish
-
Jan 2029
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age ≥ 18 years. * Referred for resection of a large (≥ 10 mm) colorectal laterally spreading tumour (LST). * Lesion judged amenable to endoscopic resection by the treating endoscopist. * Able to provide written informed consent. Exclusion Criteria: * Known concurrent or prior colorectal cancer, or another active malignancy that could contribute circulating tumour DNA. * Lesion \< 10 mm. * Inability to provide informed consent.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Advanced colorectal laterally spreading tumours (LSTS) are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.